Buena Vista (MX)
{name}
{subtitle}
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
city
~17 mi. (Monterrey, Mexico, +192 more cities)
facility
Private Practice - Dr. Joaquin Reinoso
biomarker
ER Positive, +1 more biomarker
condition
Breast Carcinoma
drug
abemaciclib, +1 more drug
drug type
hormone therapy, +1 more type
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
city
~17 mi. (Monterrey, Mexico, +144 more cities)
facility
I CAN Oncology SA de SV ( Site 0601)
condition
Clear Cell Renal Cell Carcinoma
drug
belzutifan, +3 more drugs
drug type
immunotherapy, +1 more type
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
city
~17 mi. (Monterrey, Mexico, +247 more cities)
facility
Local Institution
biomarker
ER Positive, +1 more biomarker
condition
Breast Invasive Ductal Carcinoma
drug
anthracycline, +4 more drugs
drug type
chemotherapy, +2 more types
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
city
~17 mi. (Monterrey, Mexico, +176 more cities)
facility
Christus Muguerza Clinica Vidriera ( Site 1125), +1 more facility
condition
Endometrial Carcinoma, +1 more condition
drug
chemotherapy, +2 more drugs
drug type
chemotherapy, +2 more types
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49)
city
~17 mi. (Monterrey, Mexico, +89 more cities)
facility
Christus Muguerza Clinica Vidriera ( Site 0253)
biomarker
ER Positive, +2 more biomarkers
condition
Breast Carcinoma
drug
capecitabine, +4 more drugs
drug type
chemotherapy, +1 more type
A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant Anthracycline/Taxane-Based Chemotherapy Versus Chemotherapy Alone In Patients With Operable Triple-Negative Breast Cancer
city
~17 mi. (Monterrey, Mexico, +383 more cities)
facility
Centro Médico Zambrano Hellion
biomarker
ER Negative, +2 more biomarkers
condition
Breast Carcinoma
drug
atezolizumab, +4 more drugs
drug type
chemotherapy, +1 more type
A Study of Chemo Only Versus Chemo Plus Nivo With or Without BMS-986205, Followed by Post- Surgery Therapy With Nivo or Nivo and BMS-986205 in Patients With MIBC
city
~17 mi. (Monterrey, Mexico, +177 more cities)
facility
Local Institution
condition
Bladder Carcinoma
drug
cisplatin, +3 more drugs
drug type
chemotherapy, +1 more type
Perioperative Pembrolizumab (MK-3475) Plus Neoadjuvant Chemotherapy Versus Perioperative Placebo Plus Neoadjuvant Chemotherapy for Cisplatin-eligible Muscle-invasive Bladder Cancer (MIBC) (MK-3475-866/KEYNOTE-866)
city
~17 mi. (Monterrey, Mexico, +159 more cities)
facility
Centro de Urologia Avanzada del Noreste S.A. de C.V. ( Site 0254)
condition
Superficial Bladder Urothelial Carcinoma
drug
cisplatin, +2 more drugs
drug type
chemotherapy, +1 more type
Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer (MK-3475-905/KEYNOTE-905/EV-303)
city
~17 mi. (Monterrey, Mexico, +163 more cities)
facility
Centro de Urologia Avanzada del Noreste S.A. de C.V. ( Site 0253)
condition
Bladder Urothelial Carcinoma
drug
cystectomy, +2 more drugs
drug type
chemotherapy, +3 more types